Asian Fund For Cancer Research
VC Fund
Hong Kong, Hong Kong
Asian Fund For Cancer Research is a VC fund in Hong Kong focused on Health Care and Biotechnology. The Asian Fund for Cancer Research Limited (AFCR) is committed to funding cancer research, especially those cancers prevalent in Asian populations, and promote global collaborations for high impact to save the lives of cancer patients.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Asian Fund For Cancer Research invests in
Stages Asian Fund For Cancer Research invests in
Countries Asian Fund For Cancer Research invests in
Investment Focus
Industry
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- Medical 1 (20%)
- Genetics 1 (20%)
- Bioinformatics 1 (20%)
Stage
- Grant 2 (40%)
- Seed 1 (20%)
Country
- United States 2 (40%)
- China 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Acurion
|
Acurion develops AI-driven diagnostic solutions that extract actionable genomic biomarker insights from standard pathology images to inform oncology treatment decisions. The company’s core product, OncoGaze™, analyzes digitized tumor biopsy slides to identify clinically relevant molecular features such as homologous recombination deficiency thatguide therapy selection more rapidly than conventional genomic testing. Acurion’s platform integrates into existing clinical workflows to support earlier precision medicine decisions for cancer care and is being expanded to detect additional biomarkers across various tumor types. The company collaborates with research and clinical partners to advance applications of its machine learning technology in oncology and related areas. | $4.3M / Seed / Apr 02, 2026 | |
Degron Therapeutics
|
Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment. | Grant / Dec 27, 2023 | |
Chimera Bioengineering
|
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia andlymphoma, have shown transformative results for patients unresponsive to standard therapy.However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients.Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w | $7.5M / Grant / Apr 28, 2022 | |
|
Chimera Bioengineering
|
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia andlymphoma, have shown transformative results for patients unresponsive to standard therapy.However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients.Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w | $7.5M / Grant / Apr 28, 2022 | |
|
Chimera Bioengineering
|
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia andlymphoma, have shown transformative results for patients unresponsive to standard therapy.However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients.Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w | $7.5M / Grant / Apr 28, 2022 |
Co-Investors
Bootstrap Venture Partners
1 deal together
Mesa Verde Venture Partners
1 deal together
National Foundation for Cancer Research
1 deal together
TK & Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Asian Fund For Cancer Research invest in?
Asian Fund For Cancer Research invests primarily in Health Care, Biotechnology and Medical startups, most often at Grant and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Asian Fund For Cancer Research last invest?
The most recent investment recorded for Asian Fund For Cancer Research closed in Apr 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
